soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine soul trial oral semaglutide cardiovascular

The administration says Medicare will begin covering certain GLP-1 drugs, commonly used for diabetes and weight loss, starting July 1, with out-of-pocket costs dropping to around $50 per month

With everything handled through a single complete service, you avoid the complexity of coordinating between multiple providers

"On the tablets, something seems to be putting people off

The posttranslational regulation of APE/Ref-1 activities seems to reside into two non-mutually exclusive mechanisms, i.e

Not only is this drug beneficial for reducing body weight, but it may also reduce waist circumference for those with obesity without type 2 diabetes

If the science holds up, it could be a more approachable option for a broader range of patients. The revolutionary oral medication needs to go through clinical trials and evaluations, so there is no set date when the pill will be released